BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adhoute X, Penaranda G, Raoul JL, Bourlière M. “Staging of Hepatocellular Carcinoma: BCLC system, what else!”. Liver Int. 2016; Epub ahead of print. [PMID: 26778275 DOI: 10.1111/liv.13066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Labeur TA, Berhane S, Edeline J, Blanc JF, Bettinger D, Meyer T, Van Vugt JLA, Ten Cate DWG, De Man RA, Eskens FALM, Cucchetti A, Bonnett LJ, Van Delden OM, Klümpen HJ, Takkenberg RB, Johnson PJ. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver Int 2020;40:215-28. [PMID: 31579990 DOI: 10.1111/liv.14270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
2 Wallace MC, Huang Y, Preen DB, Garas G, Adams LA, MacQuillan G, Tibballs J, Ferguson J, Samuelson S, Jeffrey GP. HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival. Dig Dis Sci. 2017;62:2182-2192. [PMID: 28547649 DOI: 10.1007/s10620-017-4622-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
3 Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016; 8(17): 703-715 [PMID: 27330679 DOI: 10.4254/wjh.v8.i17.703] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]